Background: Psoriasis is a multifactorial immune-mediated inflammatory disease, with a
chronic relapsing-remitting course, which affects 2-3% of the worldwide population. Psoriasis involves
skin, joints, or both, and it is associated with several comorbidities, including metabolic, rheumatological,
cardiovascular, psychiatric complications, and other chronic inflammatory diseases, which are the
expression of the complex underlying pathogenetic mechanism. An accurate characterization of the
immune pathways involved in psoriasis led to recognize the new molecules, (IL)17 and 23, which
become the new target of biologic therapy for moderate-to-severe plaque psoriasis.
Objective: The aim of this study is to collect data of literature about IL-17 and IL-23 inhibitors.
Methods: A descriptive review was conducted to identify the main data in the literature evaluating
novel biologic treatments currently available: IL-17 inhibitors (secukinumab, ixekizumab and
brodalumab) and IL-23 inhibitors (guselkumab, tildrakizumab and risankizumab).
Results: Dosing regimens, administration, efficacy, real-life efficacy and safety of IL-17 and IL-23
inhibitors are discussed in detail.
Conclusion: Currently approved novel biologic therapies for moderate to severe psoriasis revealed
increasing effectiveness compared to previous biological therapy and a good safety profile.